CD274 and non-small cell lung carcinoma: The latter study argues in favour of the evaluation of PD-L1 expression as a selective biomarker, and the analysis of PD-L1 in NSCLC could serve as predictor for response to PD-1 pathway inhibition and additionally as a prognostic marker for improved clinical outcome [33].